Short term effects of spironolactone on blood lipid profile: a 3-month study on a cohort of young women with hirsutism
- PMID:19843067
- PMCID: PMC2780289
- DOI: 10.1111/j.1365-2125.2009.03483.x
Short term effects of spironolactone on blood lipid profile: a 3-month study on a cohort of young women with hirsutism
Abstract
Aims: To investigate the effects of spironolactone on serum lipids in women with hirsutism over a 3-month period.
Methods: In a prospective setting, 27 hirsute women (20 with polycystic ovary syndrome and seven with idiopathic hirsutism) with a mean age of 23.0 +/- 5.1 years were studied at baseline and 3 months after receiving a daily dose of 100 mg of spironolactone. Patients did not receive any other medications and did not go through a specific diet during the study. Lipid profile, fasting blood glucose, testosterone, dehydroepiandrosterone sulphate (DHEAS) and prolactin (PRL) were measured at baseline and 3 months after therapy.
Results: Mean body mass index of patients was 26.1 +/- 5.1 kg m(-2) before treatment and 25.9 +/- 5.7 kg m(-2) after treatment (NS). The therapy was associated with a significant decline of mean high-density lipoprotein (HDL), 39.5 mg dl(-1)[95% confidence interval (CI) 35.6, 43.4]vs. 32.2 mg dl(-1) (95% CI 29.2, 35.2), and a significant increase in mean low-density lipoprotein (LDL), 133.1 mg dl(-1) (95% CI 120.2, 146) vs. 150.8 mg dl(-1) (95% CI 139.1, 162.5), and cholesterol/HDL ratio, 5 (95% CI 4.4, 5.6) vs. 6.4 (95% CI 5.7, 7.1) (P < 0.05). No significant change was noted in total cholesterol, triglyceride or fasting blood glucose levels. Serum values of testosterone, DHEAS and PRL decreased significantly after 3 months of therapy (P < 0.05).
Conclusions: Spironolactone might have adverse effects on serum lipoprotein levels by increasing LDL and decreasing HDL over a short course of treatment. While treating hirsutism with spironolactone, special care should be given to women with metabolic disorders such as dyslipidaemia.
Similar articles
- Comparison of four different treatment regimes in hirsutism related to polycystic ovary syndrome.Gökmen O, Senöz S, Gülekli B, Işik AZ.Gökmen O, et al.Gynecol Endocrinol. 1996 Aug;10(4):249-55. doi: 10.3109/09513599609012316.Gynecol Endocrinol. 1996.PMID:8908525Clinical Trial.
- Comparison of spironolactone and spironolactone plus metformin in the treatment of polycystic ovary syndrome.Diri H, Karaburgu S, Acmaz B, Unluhizarci K, Tanriverdi F, Karaca Z, Kelestimur F.Diri H, et al.Gynecol Endocrinol. 2016;32(1):42-5. doi: 10.3109/09513590.2015.1080679. Epub 2015 Sep 15.Gynecol Endocrinol. 2016.PMID:26370923Clinical Trial.
- Spironolactone in the treatment of idiopathic hirsutism and the polycystic ovary syndrome.Evans DJ, Burke CW.Evans DJ, et al.J R Soc Med. 1986 Aug;79(8):451-3. doi: 10.1177/014107688607900806.J R Soc Med. 1986.PMID:3761287Free PMC article.
- Spironolactone for hirsutism in polycystic ovary syndrome.Christy NA, Franks AS, Cross LB.Christy NA, et al.Ann Pharmacother. 2005 Sep;39(9):1517-21. doi: 10.1345/aph.1G025. Epub 2005 Aug 2.Ann Pharmacother. 2005.PMID:16076921Review.
- Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne.Farquhar C, Lee O, Toomath R, Jepson R.Farquhar C, et al.Cochrane Database Syst Rev. 2003;(4):CD000194. doi: 10.1002/14651858.CD000194.Cochrane Database Syst Rev. 2003.Update in:Cochrane Database Syst Rev. 2009 Apr 15;(2):CD000194. doi: 10.1002/14651858.CD000194.pub2.PMID:14583916Updated.Review.
Cited by
- The metabolic effects of drugs used for the treatment of polycystic ovary syndrome.Karaköse M, Cakal E, Ertan K, Delibaşı T.Karaköse M, et al.J Turk Ger Gynecol Assoc. 2013 Sep 1;14(3):168-73. doi: 10.5152/jtgga.2013.57701. eCollection 2013.J Turk Ger Gynecol Assoc. 2013.PMID:24592098Free PMC article.Review.
- Long-term spironolactone treatment reduces coronary TRPC expression, vasoconstriction, and atherosclerosis in metabolic syndrome pigs.Li W, Chen X, Riley AM, Hiett SC, Temm CJ, Beli E, Long X, Chakraborty S, Alloosh M, White FA, Grant MB, Sturek M, Obukhov AG.Li W, et al.Basic Res Cardiol. 2017 Sep;112(5):54. doi: 10.1007/s00395-017-0643-0. Epub 2017 Jul 29.Basic Res Cardiol. 2017.PMID:28756533Free PMC article.
- Spironolactone revisited.Polyzos SA, Kountouras J, Zavos C, Deretzi G.Polyzos SA, et al.J Clin Hypertens (Greenwich). 2011 Oct;13(10):783-4. doi: 10.1111/j.1751-7176.2011.00484.x. Epub 2011 Jul 18.J Clin Hypertens (Greenwich). 2011.PMID:21974769Free PMC article.No abstract available.
- A systematic review and meta-analysis of the impact of mineralocorticoid receptor antagonists on glucose homeostasis.Korol S, Mottet F, Perreault S, Baker WL, White M, de Denus S.Korol S, et al.Medicine (Baltimore). 2017 Dec;96(48):e8719. doi: 10.1097/MD.0000000000008719.Medicine (Baltimore). 2017.PMID:29310346Free PMC article.Review.
- Is there a potential association between spironolactone and the risk of new-onset diabetes in a cohort of older patients with heart failure?Korol S, White M, O'Meara E, Rouleau JL, White-Guay B, Dorais M, Ahmed A, de Denus S, Perreault S.Korol S, et al.Eur J Clin Pharmacol. 2019 Jun;75(6):837-847. doi: 10.1007/s00228-018-02615-8. Epub 2019 Feb 13.Eur J Clin Pharmacol. 2019.PMID:30758517
References
- Garthwaite SM, McMahon EG. The evolution of aldosterone antagonists. Mol Cell Endocrinol. 2004;217:27–31. - PubMed
- Zawadski JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine F, editors. Polycystic Ovary Syndrome. Boston, MA: Blackwell Scientific; 1992. pp. 377–84.
- Searafini P, Lobo RA. The effects of spironolactone on adrenal steroidogenesis in hirsute women. Fertil Steril. 1985;44:595–9. - PubMed
- Milewicz A, Silber D, Kirschner M. Therapeutic effects of spironolactone in polycystic ovary syndrome. Obstet Gynecol. 1983;61:429–32. - PubMed
- Falch DK, Schreiner A. The effect of spironolactone on lipid, glucose and uric acid levels in blood during long-term administration to hypertensives. Acta Med Scand. 1983;213:27–30. - PubMed
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous